The Latest Breaking News from Pfizer

Roche said Monday it would buy an experimental immunology drug from Roivant and Pfizer for $7.1 billion. But ROIV stock sank.

Roivant, the drug developer founded by Republican Presidential candidate Vivek Ramaswamy, has sold the rights to its bowel disease treatment for $7.1 billion.

Pfizer & KIMS Hospital in Hyderabad inaugurated a CoE for Adult Vaccination to equip HCPs & educate patients on enduring advantages of vaccinations. It will reinforce immunisation against Pneumococcal, Hepatitis A/B, HPV & Influenza. CoE symbolises commitment to protecting individuals against respiratory threats & enhancing quality of life.

The fallout from the Israel-Hamas war has spilled into workplaces everywhere, with corporate leaders from the highest ranks of prominent companies weighing in with their views while workers complain their voices are not being heard

One of the most effective treatments for COVID is going to get a lot more expensive, but Pfizer insists it's fine

Pfizer is hiking its Paxlovid price to $1,390 for a five-day course of the Covid pill. But Pfizer stock fell early Thursday.

Back in May, the World Health Organization declared an end to the global Public Health Emergency for Covid-19. Despite the end of the pandemic, however, the healthcare industry is still feeling its effects. Vaccine makers and pharmacy chains are seeing a steep decline in the number of people getting Covid...

Many people first became familiar with the term “mRNA” when Pfizer’s and Moderna’s COVID vaccines were rolled out. In the simplest terms, mRNA, which stands for messenger ribonucleic acid, is a type of genetic material that gives cells in our bodies instructions to make specific proteins.

The stock market remained positive with the major indexes all gaining around 1%. Retail stock rises on news it will get added to the S&P 500 Index.

Moderna stock and BioNTech stock led a sell-off Monday among Covid vaccine makers after Pfizer slashed its full-year guidance.

Shares of Pfizer are falling before the opening bell as the company cut its full-year outlook, citing declining sales of its COVID-19-related products